FCGR2A and Miyoshi myopathy: In conclusion, TIGIT, but not PD-1, was expressed on activated CD8+ T cells in the PBSC grafts of patients with MM and our preclinical data highlight that the antimyeloma efficacy of TIGIT inhibition was highly dependent on FcγR engagement.